Medivis

Medivis operates at the intersection of medical imaging, surgical navigation, augmented reality, and AI. Its products translate patient CT and MRI data into interactive 3D views and carry that information into planning and intraoperative guidance. The company’s FDA-cleared Spine Navigation and Cranial Navigation products give it a more clinically specific proposition than general-purpose AR or visualization tools: they target defined surgical workflows and have regulatory clearances for their stated uses. Its portfolio also includes SurgicalAR® and the AnatomyX® education platform, while a supervised robotics program is described as in development. Novarad is a relevant adjacent competitor: a 2024 litigation headline concerned its dispute with Medivis over an augmented-reality navigation system, although the available details do not support a broader comparison of product capabilities or market share. The company’s differentiation is best assessed through its patient-specific imaging workflow, surgical guidance products, and regulatory milestones—not through unsupported claims of category leadership. Its $25 million in disclosed funding and 11–50 employee range indicate a substantially smaller operating scale than established medical-device incumbents.

Medivis’s development shows a progression from early-stage financing to commercial and regulatory milestones across multiple surgical specialties. The company raised two Seed rounds—$2.3 million in February 2019 and $2.7 million in February 2020—followed by a $20 million Series A led by Thrive Capital on June 13, 2023. The Series A was the most recent disclosed round and accounts for most of the company’s $25 million total funding. A key product inflection point came on April 2, 2025, when Medivis announced FDA 510(k) clearance and U.S. commercialization of Spine Navigation. On December 16, 2025, it announced FDA clearance for Cranial Navigation, extending its regulated navigation portfolio into cranial neurosurgery. Those clearances mark a shift beyond platform development toward products intended for clinical use; they do not, by themselves, establish adoption or revenue growth. The company also describes a supervised robotics program building on its registration, tracking, and approved-plan capabilities, but it remains in development. The disclosed employee band is 11–50, and a hiring signal notes one open role.